Previous 10 |
home / stock / seovf / seovf news
(via TheNewswire) LONDON, ONTARIO / TheNewswire / April 11, 2019 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the first Cell Pouch(TM) transplant of insulin-producing cells in its U.S. Phase I/II clinical trial...
(via TheNewswire) LONDON, ONTARIO / TheNewswire / February 11, 2019 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the first patient implanted with Sernova's Cell Pouch(TM) in the Phase I/II clinical trial evalua...
(via TheNewswire) Sernova Adds Scientific Advisory Board Expertise as it Broadens its Therapeutic Cell Therapy Applications for Rare Blood Diseases LONDON, ONTARIO / TheNewswire / January 30, 2019 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage regene...
The following slide deck was published by Sernova Corp. in conjunction with this Read more ...
(via TheNewswire) LONDON, ONTARIO / TheNewswire / January 28, 2019 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present the latest company overview an...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...